• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Diamyd Medical

1.12 SEK

+0.54 %

Less than 1K followers

DMYD B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.54 %
-7.43 %
-92.37 %
-90.04 %
-88.64 %
-88.64 %
-86.48 %
-96.59 %
-62.63 %

Diamyd Medical is active in diabetes research. The company has developed a vaccine that contains the active ingredient and molecule GAD, a substance that has the potential to be an important part of the prevention of diabetes treatments in the future. The company has operations on a global level with the largest presence in the Nordic region. The headquarters are located in Stockholm.

Read more
Market cap
173.89M SEK
Turnover
2.41M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
ShowingAll content types

Forum discussions
The intention was to publish the report before the readout, but the new financing package complicated things so much that practically everything had to be recalculated and models updated. On the other hand, the new financing package combined with market movements led to a heuristically...
3/30/2026, 2:53 PM
by Gubrick
9
To all you investors who believed in diabetes treatment drugs and lost your money in Diamyd, I recommend turning your gaze to a company called Nektar - $NKTR. They have a very interesting diabetes trial underway with a drug that targets Tregs, aiming to restore the body’s own immune...
4/23/2026, 11:15 AM
by SeekingAlpha
8
New information has come out, nothing positive. diamyd.com Diamyd Medical discontinues DIAGNODE-3 following evaluation confirming...
4/10/2026, 6:40 PM
6
There’s no point in selling in this bankruptcy. It still amazes me how the difference can be so radical compared to previous data that it’s not even worth continuing the study to the end. The probability that previous positive results were just a coincidence is quite small, isn’t...
4/13/2026, 9:38 AM
4
Good to know, the expenses stop running and they can do the trial’s autopsy. I’ll hold the earthly remains of the position out of academic interest.
4/10/2026, 7:28 PM
by Clark kent
4
Ulf stepped down from the CEO role after ten years. He was replaced by Diamyd founder, chairman of the board, and former CEO, Anders Essen-Möller. Anders is already a respectable 85 years old and founded Diamyd when his daughter fell ill with type 1 diabetes. A recent interview about...
4/27/2026, 11:35 AM
3
Great find! If you’re up for it, this might be the place for a new thread—just remember to tag it as comprehensively as possible, otherwise the thread might not be found. Regardless, the drug seems to be quite far along already, and there seems to be a market for it.
4/29/2026, 4:58 PM
by Hawkmountdiver
2
Read more on our forum
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
24.6.
2026

Interim report Q3'26

7.10.
2026

Annual report '26

3.12.
2026

General meeting '26

Regulatory press releaseyesterday

Diamyd Medical AB: Diamyd Medical provides update on ongoing Activities

Diamyd Medical
Regulatory press release5/22/2026, 6:30 AM

Diamyd Medical AB: Diamyd Medical announces that Niklas Axelsson has decided to leave his position as CFO to take on a new role in another company

Diamyd Medical
Press release5/20/2026, 7:59 AM

DNB Carnegie Access: Diamyd Medical: GMP milestone for Umeå facility

Diamyd Medical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release5/20/2026, 6:30 AM

Diamyd Medical AB: Diamyd Medical receives GMP certification and manufacturing authorization for biological investigational medicinal products for human use

Diamyd Medical
Regulatory press release5/11/2026, 6:30 AM

Diamyd Medical AB: Diamyd Medical provides an update on strategic review and financial position

Diamyd Medical
Press release5/5/2026, 10:33 AM

DNB Carnegie Access: Diamyd Medical: GMP progress and latest news flow

Diamyd Medical
Regulatory press release5/5/2026, 6:30 AM

Diamyd Medical AB: Diamyd Medical strengthens its position in the manufacturing of biological medicines - positive feedback from the Swedish Medical Products Agency

Diamyd Medical
Regulatory press release4/24/2026, 8:30 AM

Diamyd Medical AB: Diamyd Medical announces governance and leadership update

Diamyd Medical
Regulatory press release4/23/2026, 9:15 AM

Diamyd Medical AB: Diamyd Medical announces governance and leadership changes

Diamyd Medical
Press release4/13/2026, 6:59 AM

DNB Carnegie Access: Diamyd Medical: Discontinues DIAGNODE-3 and initiates strategic review

Diamyd Medical
Regulatory press release4/10/2026, 5:10 PM

Diamyd Medical AB: Diamyd Medical discontinues DIAGNODE-3 following evaluation confirming futility; initiates strategic review

Diamyd Medical
Regulatory press release4/8/2026, 1:10 PM

Diamyd Medical AB: Bulletin from Diamyd Medical's Extraordinary General Meeting 2026

Diamyd Medical
Press release3/31/2026, 4:19 AM

DNB Carnegie Access: Diamyd Medical: Awaiting clarity on next steps – valuation reset

Diamyd Medical
Press release3/30/2026, 3:00 PM

DNB Carnegie Access: Diamyd Medical - DIAGNODE-3 interim readout

Diamyd Medical
Press release3/30/2026, 5:35 AM

DNB Carnegie Access: Diamyd Medical: Reports negative interim results of Phase III trial

Diamyd Medical
Regulatory press release3/29/2026, 8:45 PM

Diamyd Medical AB: Diamyd Medical updates on the interim efficacy analysis of Phase 3 DIAGNODE-3 trial

Diamyd Medical
Regulatory press release3/27/2026, 7:20 PM

Diamyd Medical AB: Diamyd Medical reports negative interim results of Phase 3 DIAGNODE-3 trial

Diamyd Medical
Press release3/26/2026, 8:14 AM

DNB Carnegie Access: Diamyd Medical: Capital first, data next – Q2 2025/26 review – correction

Diamyd Medical
Press release3/25/2026, 5:07 PM

DNB Carnegie Access: Diamyd Medical: Capital first, data next – Q2 2025/26 review

Diamyd Medical
Regulatory press release3/25/2026, 7:15 AM

Diamyd Medical AB: Quarterly Report 2 25/26

Diamyd Medical